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I.1 Cell membrane 
The cell membrane or plasma membrane is a biological membrane that separates 
the interior of all cells from the outside environment. The membrane acts as a boundary, 
holding the cell constituents together and keeping other substances from entering. The 
cell membrane is selectively permeable to specific molecules. The all membrane allows 
nutrients and other essential elements to enter the cell and waste materials to leave the 
cells.1 The basic function of the cell membrane is to protect the cell from its 
surroundings. It consists of the lipid bilayer with embedded proteins (Fig. 1.1).2 Cell 
membranes are involved in a variety of cellular processes such as cell adhesion, ion 
conductivity and cell signaling and serve as the attachment surface for several 
extracellular structures, including the cell wall. Cell membranes can be artificially 
reassembled.3,4 
 The cell membrane consists primarily of a thin layer of amphipathic 
phospholipids which spontaneously arrange so that the hydrophobic "tail" regions are 
isolated from the surrounding polar fluid, causing the more hydrophilic "head" regions to 
associate with the intracellular and extracellular faces of the resulting bilayer. This forms 
a continuous, spherical lipid bilayer. Forces such as van der Waals, electrostatic, 
hydrogen bonds, and noncovalent interactions, contribute to the formation of the lipid 
bilayer. Hydrophobic interactions are the major driving force in the formation of lipid 
bilayers. Lipid bilayers are generally impermeable to ions and polar molecules. The 
arrangement of hydrophilic heads and hydrophobic tails of the lipid bilayer prevent polar 
solutes (e.g. amino acids, nucleic acids, carbohydrates, proteins, and ions) from diffusing 
across the membrane, but generally allows for the passive diffusion of hydrophobic 
molecules (Fig. 1.1). This affords the cell the ability to control the movement of these 
substances via transmembrane protein complexes such as pores, channels and gates. 
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Figure 1.1: Cell membrane structural components 
Cell membrane is composed of a double layer (bilayer) of lipids. Membrane proteins are attached to lipid 
bilayer (protein colored red and blue).  
I.2 Lipids 
 The cell membrane consists of three classes of amphipathic lipids: phospholipids, 
glycolipids, and cholesterols. The amount of each component depends upon the type of 
cells, but in many kinds of cells phospholipids are the most abundant.5 Fig. 1.2 show the 
classification of lipids.  
I.2.1 Phospholipid 
 Phospholipids are a class of lipids that is a major component of cell membranes 
and can form lipid bilayers. Most phospholipids contain a diglyceride, a phosphate group, 
and a simple organic molecule such as choline; one exception to this rule is 
sphingomyelin, which is derived from sphingosine instead of glycerol. The 'head' is 
hydrophilic (attracted to water), while the hydrophobic 'tails' are repelled by water and 
are forced to aggregate. The hydrophilic head contains the negatively charged phosphate 
group, and may contain other polar groups. The hydrophobic tail usually consists of long 
fatty acid hydrocarbon chains. When placed in water, phospholipids form a variety of 
structures depending on the specific properties of the phospholipid.6 
http://micro.magnet.fsu.edu/cells/plasmamembrane/plasmamembrane.html 
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Cholesterol  
Phosphatidic acids (PAs) are the acid forms of phosphatidates, a part of common 
phospholipids, and major constituents of cell membranes. PAs are the simplest diacyl-
glycerophospholipids.7 It is known to have signaling functions in animal cells, by specific 
binding to particular proteins.8 PA consists of a glycerol backbone, with, in general, a 
saturated fatty acid bonded to carbon-1, an unsaturated fatty acid bonded to carbon-2, and 
a phosphate group bonded to carbon-3.7,9 
Phosphatidylethanolamine (PE) is a lipid found in biological membranes.10 PE is 
found in all living cells, composing 25% of all phospholipids. As a polar head group, PE 
creates a more viscous lipid membrane compared to phosphatidylcholine (PC). PE 
consists of a combination of glycerol esterified with two fatty acids and phosphoric acid. 
Whereas the phosphate group is combined with choline in phosphatidylcholine, it is 
combined with the ethanolamine in PE.   
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Major classes of lipid molecules 
The chemical structure of phospholipid, glycolipid and cholesterol shows their head group and tail.  
 
http://en.wikipedia.org/wiki/Cell_membrane   
http://en.wikipedia.org/wiki/Cholesterol 
  
 
11 
Phosphatidylcholine (PC) is one of the most widely distributed lipids in the cell 
membrane of animals and plants. The phospholipid is composed of a choline head group 
and glycerophosphoric acid with a variety of fatty acids. Phosphatidylcholine is a major 
constituent of cell membranes. Phosphatidylcholine is more commonly found in the outer 
leaflet of a cell membrane. It is thought to be transported between membranes within the 
cell by phosphatidylcholine transfer protein (PCTP).11 
Phosphatidylinositol (PI) is a negatively charged phospholipid and a minor 
component in the inner side of eukaryotic cell membranes. The phosphatidylinositol can 
be phosphorylated to form phosphatidylinositol phosphate (PIP), phosphatidylinositol 
bisphosphate (PIP2) and phosphatidylinositol trisphosphate (PIP3). PIP, PIP2 and PIP3 are 
collectively called phosphoinositides. PI has a polar and non-polar region, making the 
lipid an amphiphile. PI is classified as a glycerophospholipid that contains a glycerol 
backbone, two non-polar fatty acid tails, and a phosphate group substituted with an 
inositol polar head group. 
Phosphatidylserine (PS), having L-serine in its head group, is the most abundant 
anionic lipids. PS has an important role in the regulation of apoptosis;12 moreover, it can 
affect the non-specific electrostatic interactions among membranes, ions, and membrane 
binding proteins.8,12 PS usually kept on the inner-leaflet of cell membranes. When a cell 
undergoes apoptosis, phosphatidylserine is no longer restricted to the inner part of the 
membrane.13   
Sphingomyelin (SM) is believed to be the only cell membrane phospholipid not 
derived from glycerol. Like all sphingolipids, has the ceramide core (sphingosine bonded 
to a fatty acid via an amide linkage). In addition, it contains one polar head group, which 
is either phosphocholine or phosphoethanolamine. The function of sphingomyelin 
remained unclear until recently, when it was found to have a role in signal transduction.14 
I.2.2 Glycolipid 
Glycolipids are lipids with a carbohydrate attached. Their role is to provide 
energy and also serve as markers for cellular recognition. They occur where a 
carbohydrate chain is associated with phospholipids on the exoplasmic surface of the cell 
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membrane. The most common types of glycolipids are glycosphingolipids, which are 
made up of ceramides connected to a glycan. Ceramides are made up of fatty 
acids connected to sphingosines, which are simply amino alcohols that are commonly 
found in nerve tissue.  
Ganglioside is a molecule composed of a glycosphingolipid (ceramide and 
oligosaccharide) with one or more sialic acids linked on the sugar chain. NeuNAc, an 
acetylated derivative of the carbohydrate sialic acid, makes the head groups of 
gangliosides anionic at pH 7, which distinguishes them from globosides. gangliosides 
have been found to be highly important molecules in immunology. Natural and 
semisynthetic gangliosides are considered possible therapeutics for neurodegenerative 
disorders.15 
I.2.3 Cholesterol  
Cholesterol is an essential structural component of mammalian cell membranes 
and is required to establish proper membrane permeability and fluidity. Cholesterol is 
required to build and maintain membranes; it modulates membrane fluidity over the 
range of physiological temperatures. The hydroxyl group on cholesterol (Fig. 1.2) 
interacts with the polar head groups of the membrane phospholipids and sphingolipids, 
while the bulky steroid and the hydrocarbon chain are embedded in the membrane, 
alongside the nonpolar fatty-acid chain of the other lipids. Through the interaction with 
the phospholipid fatty-acid chains, cholesterol increases membrane packing, which 
reduces membrane fluidity.16 The structure of the tetracyclic ring of cholesterol 
contributes to the decreased fluidity of the cell membrane as the molecule is in a trans 
conformation making all but the side chain of cholesterol rigid and planar.17 
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I.3 Membrane Protein 
A membrane protein is a protein molecule that is attached to, or associated with 
the membrane of a cell. More than half of all proteins interact with membranes. These 
proteins are specifically targeted to different types of biological membranes. Membrane 
proteins can be divided into three classes according to the way of the interaction with 
membranes; integral protein, peripheral protein and lipid-anchored protein (Fig. 1.3).19 
I.3.1 Integral membrane protein 
An integral membrane protein (IMP) is a protein molecule (or assembly of 
proteins) that is permanently attached to the biological membrane. Proteins that cross the 
membrane are surrounded by "annular" lipids, which are defined as lipids that are in 
direct contact with a membrane protein. Three-dimensional structures of only ~160 
different integral membrane proteins are currently determined at atomic resolution by X-
ray crystallography or nuclear magnetic resonance spectroscopy due to the difficulties 
with extraction and crystallization. In addition, structures of many water-soluble domains 
of IMPs are available in the Protein Data Bank. Integral membrane proteins are further 
classified by the number of the span; a single-pass or a multi-pass transmembrane 
protein. A single-pass membrane protein is exemplified by cytokine receptors and 
receptor tyrosine kinases. A typical example of multi-pass transmembrane proteins is a 
seven-pass G-protein coupled receptor (GPCR). All transmembrane proteins are IMPs, 
but not all IMPs are transmembrane proteins.19 
I.3.2 Peripheral membrane protein 
Peripheral membrane proteins are proteins that bind only temporarily to the 
biological membrane with which they are associated. These molecules attach to integral 
membrane proteins, or penetrate the peripheral regions of the lipid bilayer. The regulatory 
protein subunits of many ion channels and transmembrane receptors are usually defined 
as peripheral membrane proteins. In contrast to integral membrane proteins, peripheral 
membrane proteins tend to collect in the water-soluble component, or fraction, of all the 
proteins extracted during a protein purification procedure. Proteins with GPI anchors are 
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an exception to this rule and can have purification properties similar to those of integral 
membrane proteins. Peripheral membrane proteins may interact with other proteins or 
directly with the lipid bilayer. In the latter case, they are then known as amphitropic 
proteins.20 Some proteins, such as G-proteins and certain protein kinases, interact with 
transmembrane proteins and the lipid bilayer simultaneously. 
I.3.3 Lipid-anchored membrane protein 
Lipid-anchored membrane proteins are bound to membranes by covalently 
attached lipid molecules.18 The exact function of the anchor protein has been the subject 
of much speculation, but it appears to act as an intracellular signal that targets proteins to 
the apical surface in polarized cells. 
 
 
 
 
 
 
 
Figure 1.3: Membrane proteins structure 
Membrane proteins integrated with membrane.   
 
 
 
www.chem.arizona.edu/faculty_profile/wirt/membrane_proteins.html 
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I.4 Epitope Peptide 
An epitope peptide is the part of an antigen that is recognized by the immune 
system, specifically antibodies, T cells.  The part of an antibody that recognizes the 
epitope is called a paratope. Although epitopes are usually non-self proteins, sequences 
derived from the host that can be recognized are also epitopes. T cell epitopes are 
presented on the surface of an antigen-presenting cell, where they are bound to major 
histocompatibility complex (MHC) molecules (Fig. 1.4). Human MHC molecules are 
usually called as human leukocyte antigen (HLA). HLA molecules are categorized into 
class Ι and ΙΙ. MHC class I molecules is a heterodimer of heavy chain called α chain. T 
cell epitopes presented by MHC class I molecules are typically peptides between 8 and 
11 amino acids in length, whereas MHC class II molecules present longer peptides, 13-17 
amino acids in length,21 and non-classical MHC molecules also present non-peptidic 
epitopes such as glycolipids. 
  
 
 
 
 
 
 
 
Figure 1.4: Binding mechanism of epitope peptide with MHC molecule.   
MHC class I proteins are express on the surface of cells. They are bind to epitope peptide and display on 
the cell surface.  
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I.5 Molecular Dynamics Simulations 
Molecular dynamics (MD) simulation is a computer simulation of physical 
movements of atoms and molecules. The atoms and molecules are allowed to interact for 
a period of time, giving a view of the motion of the atoms. Molecular dynamics probes 
the relationship between molecular structure, movement and function.22 The trajectories 
of molecules and atoms are determined by numerically solving the Newton's equations of 
motion for a system of interacting particles, where forces between the particles and 
potential energy are defined by molecular mechanics force fields. MD simulation requires 
two things to start; parameters and an initial structure. 
In MD simulations, some approximations are applied to; an atom is represented as 
a hard sphere with a single point charge; a covalent bond an angle formed among three 
connected atoms are described as springs with the specific spring constants; moreover, 
interatomic forces are calculated based on the van der Waals (vdW) interaction energy 
and the electrostatic energy between any two non-bonded atoms. Theses point charges, 
spring constants, and vdW coefficients are called “force field parameters”, and a system 
described by them is called “force field”. AMBER23 and CHARMM24 exemplify the 
extensively used force field parameters and the MD simulation program packages, for 
example, AMBER, CHARMM, NAMD.25  
Another requirement to start MD simulations is getting an initial structure of a 
target molecule. In the case of a protein, its initial structure can be obtained from the 
Protein Data Bank (PDB) as a text file containing the three-dimensional coordinates of 
the atoms determined by X-ray crystallographic analysis or nuclear magnetic resonance 
(NMR). But only 2% of crystal structures deposited in the Protein Data Bank are 
membrane proteins.26 Thus, an important application of MD simulations is in the field of 
membrane proteins, due to the limited high-resolution structural information.27,28 Hence, 
alternative way to get the initial structure must be taken; molecular modeling. However, 
the molecular modeling of membranes is a quite time-consuming task even for experts of 
MD simulations, because of the complexity of the membranes as mentioned above.  
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As a result, MD simulations in the biological field have been intensively focused 
on soluble proteins so that most of the force field parameters were developed and 
optimized for soluble proteins.29,30  
I.6 Analysis of MD simulation 
 The simulation system should be equilibrated enough for reliable analysis. One of 
the stranded techniques to confirm the equilibration is to measure root mean square 
deviation (RMSD) value between snapshot structure acquired at a designated time point 
and the initial structure at starting point. RMSD measurement was performed, using the 
ptraj module of AMBER program.23 If the time evolution of RMSD value shows constant, 
the molecule fluctuates in a single conformation and the calculation system is assumed to 
be equilibrated. RMSD for MD simulation computed with respect to the Cα, N, and C 
main chain atoms.   
 Principal component analysis31,32 is another method to confirm the equilibration 
of the computational system. Since protein has many confirmations because of large 
amount of atoms composing the structure, there exist several minimization points in 
potential energy. If the energy barrier separating potential minima is low enough, the 
structure fluctuates among the energy minimization structures during MD simulation. 
When the system is in structural equilibration the structure fluctuates only around the 
adjacent of stable minimum point. 
 Protein flexibility is highly correlated with protein functions.33 Thermal motion is 
one of the most important motions within protein structures. The B-factor (atomic 
displacement parameter) in protein crystal structures reflects the fluctuation of an atom 
about its average position. A large B-factor indicates high mobility of individual atoms 
and side chains. B-factors provide a solid experimental source of information about the 
dynamics of a protein. B-factors have a variety of applications, such as predicting protein 
flexibility,34 studying protein thermal stability,35 analyzing active sites,36 correlating side-
chain mobility with conformation,37 analyzing protein disordered regions11,12 and 
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investigating protein dynamics. B-factors have been predicted from protein sequences, 
protein atomic coordinates and protein electron density maps. 
Computational methods that combine molecular mechanics energy and implicit 
solvation models, such as Molecular Mechanics/Poisson-Boltzmann Surface Area 
(MM/PBSA) and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA), 
have been widely exploited in free energy calculations.38,39 MM/PBSA and MM/GBSA 
allow for rigorous free energy decomposition into contributions originating from different 
groups of atoms or types of interaction.40,41 In MM/PBSA or MM/GBSA, the binding 
free energy (∆Gbind) between a ligand (L) and a receptor (R) to form a complex RL is 
calculated as 
∆Gbind = ∆H - T∆S ≈ ∆EMM  + ∆Gsol - T∆S 
∆EMM =  ∆Einternal  + ∆Eelectrostatic  + ∆Evdw 
∆Gsol =  ∆GPB/GB + ∆GSA 
where ∆EMM, ∆Gsol and -T∆S are the changes of the gas phase MM energy, the 
solvation free energy, and the conformational entropy upon binding, respectively. ∆EMM 
includes ∆Einternal (bond, angle, and dihedral energies), ∆Eelectrostatic (electrostatic), and 
∆Evdw (van der Waals) energies. ∆Gsol is the sum of electrostatic solvation energy (polar 
contribution), ∆GPB/GB, and the nonelectrostatic solvation component (nonpolar 
contribution), ∆GSA. The polar contribution is calculated using either the GB or PB model, 
while the nonpolar energy is estimated by solvent accessible surface area (SASA). The 
conformational entropy change T∆S is usually computed by normal-mode analysis on a 
set of conformational snapshots taken from MD simulations. 
. 
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I.7 This Thesis  
This thesis describes the following two main subjects; 
1. Influence of lipid composition on the structural stability of G-protein coupled 
receptor. (Chapter II) 
2. Computational analysis on the binding of epitope peptide to human leukocyte 
antigen class I molecule A*2402 subtype. (Chapter III) 
 
In the first topic, MD simulation of three kinds of states: apo- (without ligand), 
antagonist- (ligand) and antagonist-bound (ligand) G-protein coupled receptor. These 
three kinds of GPCRs were embedded in four types of lipid membranes: (i) pure 
POPC(palmitoyl-oleoyl-phosphatidyl-choline), (ii) POPC/CHL(cholesterol), (iii) 
POPC/CHL/GM1(GM1 ganglioside), (iv) POPC/POPE(palmitoyl-oleoyl-phosphatidyl-
ethanolamine)/CHL/SM(sphingomyelin). We investigated the effect of different kinds of 
lipid bilayers on the structural stability of GPCR.  
 The second topic, MD simulation on the complex of 9-mer epitope peptides and 
HLA molecule and subsequently estimated the binding affinity using molecular 
mechanics/generalized-Born surface area method combined with normal mode analysis. 
We investigated peptide binding affinity to HLA molecule. Details are described in 
Chapter III. 
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Chapter II 
Influence of lipid composition on the structural stability 
of G-protein coupled receptor 
Abstract 
β2 adrenergic receptor (β2AR) is a kind of G-protein coupled receptors (GPCRs) 
which transduce a wide range of extracellular signals into intracellular messages 
responsible for the regulation of diverse cell functions. Because of their functional 
ubiquity, GPCR is one of the most important drug targets in pharmaceutical industry. 
Although recent crystallographic studies provided both the active and the inactive states 
of some families of GPCRs, the influence of lipid composition of bilayer membrane on 
their activation is still poorly understood.  In this work, we address the influence of lipid 
composition on the structural stability of GPCR, performing molecular dynamics 
simulations of three kinds of states: apo-, and agonist epinephrine-, or antagonist 
alprenolol-bound β2AR. These three kinds of β2ARs were embedded in four types of lipid 
membranes: (i) pure POPC(palmitoyl-oleoyl-phosphatidyl-choline), (ii) 
POPC/CHL(cholesterol), (iii) POPC/CHL/GM1(GM1 ganglioside), (iv) 
POPC/POPE(palmitoyl-oleoyl-phosphatidyl-ethanolamine)/CHL/SM(sphingomyelin). 
The side chains of Lys2676.29 and Asp3317.58 showed different conformations among the 
three states in all types of lipid membranes. The distances between Lys2676.29 and 
Asp3317.58 of apo- and alprenolol-bound β2ARs are smaller than that of the epinephrine-
bound β2AR. In contrast, β2ARs in POPC/CHL bilayer were unstable in which the salt 
bridge; i.e., ionic lock, was not formed between Arg1313.50 and Glu2686.30. We have also 
examined the distribution of lipid molecules. A strong hydrophobic interaction between 
CHL and β2AR was observed at transmembrane helix5 in POPC/CHL/GM1 and 
POPC/POPE/CHL/SM membranes. These results suggest that the lipid composition 
strongly affects the conformation of GPCR and essentially concerns the GPCR activation.  
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II.1 Introduction 
G-protein coupled receptors (GPCRs) are the largest class of versatile signaling 
molecules that are responsible for the signal transduction across cellular membranes in 
response to extracellular hormones or neurotransmitters, etc.42 Accordingly, GPCRs have 
been the major drug targets in pharmaceutical industry. The β2 adrenergic receptor 
(β2AR) is well studied member of GPCR families, which mediates the effects of 
catecholamine, epinephrine, and norepinephrine.43 β2AR plays an important regulatory 
role in a variety of cells and organs and is an important therapeutic target in the treatment 
of airway and cardiovascular disease.44 Like other GPCRs, the conformation of β2AR is 
known to vary between the inactive and the active states. The conformational change 
induced by the binding of extracellular ligands to β2AR results in the G-protein-mediated 
cell signaling.  
The protein structures vary, depending on the inactive and the active signaling 
state of the receptor. The crystal structures of two GPCRs,  β2AR and bovine rhodopsin, 
have recently been revealed both for the active state (agonist-bound) and the inactive 
state (antagonist-bound).45-47 The human β2AR is one of the first GPCRs to be identified 
through ligand binding, and is the first neurotransmitter receptor to be cloned.48 Its 
structure has been determined in complex with various kinds of ligands including inverse 
agonists, full agonists and antagonists.49-51 In the previous computational studies, the 
inactive state of β2AR in complex with agonist or antagonist has been embedded in a 
lipid bilayer membrane composed of a single type of lipid molecule (palmitoyl-oleolyl-
phosphatidyl-ethanolamine, POPE bilayer or palmitoyl-oleoyl-phosphatidyl-choline, 
POPC bilayer).47,52 Recent studies suggest that rafts, special kind of micro-domains that 
are enriched by cholesterol (CHL), play an essential role in the signaling by enabling the 
conformational change of GPCRs.53-56 In the present study, we analyze the inactive 
structure of β2AR without ligand (apo) or in complex with ligand (agonist epinephrine 
and antagonist alprenolol) embedded in the palmitoyl-oleoyl-phosphatidyl-choline 
(POPC) bilayer, cholesterol (CHL) containing POPC,  GM1 ganglioside containing 
POPC/CHL, or the mixed membrane consisting of POPC, palmitoyl-oleoyl-phosphatidyl-
ethanolamine (POPE), CHL, sphingomyelin (SM). The last one imitates the biological 
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membranes, using a software program developed for modeling various types of lipid 
membranes.57 The mixed membrane, POPC/POPE/CHL/SM, was created referring the 
studies on the lipid composition of biological membrane.58-61 In erythrocyte, the lipid 
bilayer was composed of equal ratios by weight of cholesterol (CHL) and 
phospholipids.59 The three major phospholipids are POPC, POPE and SM.59,61 Therefore, 
our simulation using the membrane model with the mixed lipid composition will be 
helpful to understand the structural perturbation of GPCRs in the biological membrane.  
In the diverse intracellular signaling process, β2ARs constitute multiple receptor 
conformation in its active and inactive states. Biochemical and biophysical studies 
suggested that the rearrangement of helix3 and helix6 was involved in the activation 
process of rhodopsin and β2AR.
62,63 Moreover the inactive rhodopsin structures 
demonstrated that highly conserved residue Arg1313.50 (superscripts refer to Ballesteros-
Weinstein residue numbering scheme64) at the end of intracellular part of helix3 formed a 
salt bridge; i.e., ionic lock, with acidic residue Glu2686.30 at the end of intracellular part 
of helix6.65-67 In contrast, an activated rhodopsin structure showed the break of the ionic 
lock between Arg1313.50 and Glu2686.30.62,68,69 Although the crystal structure of the 
inactive β2AR lacks the salt bridge between Arg131
3.50 and Glu2686.30, several 
biochemical studies have suggested that an ionic lock between Arg1313.50 and Glu2686.30 
is established in β2AR as well as other GPCRs.
47,70-74 The disruption of ionic interaction 
between the highly conserved D(E)RY residue at helix3 and an acidic residue at helix6 is 
considered to promote the receptor activation and to be highly related to the 
conformational change of  both rhodopsin and β2AR.
62,70,74   
For understanding of the activation mechanism of β2AR embedded in a lipid 
bilayer membrane, in this work, we have performed molecular dynamics (MD) 
simulation by constructing computational models for ligand bound and unbound β2AR 
embedded in four types of lipid bilayer membranes; pure POPC, POPC/CHL, 
POPC/CHL/GM1 and POPC/POPE/SM/CHL, solvated with water molecules, and 
executed 100 ns MD simulations for every model system with applying periodic 
boundary conditions. We particularly address the effect of lipid composition of bilayer 
membrane on the ligand bound and unbound β2AR receptor. Several huge MD 
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simulations previously characterized the dynamics of rhodopsin and/or β2AR and some 
simulation studies on β2AR mainly focused on the formation of ionic lock.
47,75-79 
Contrary to the huge simulations, a few reports54,55,80 have indicated that lipid 
composition modulates the activity of GPCRs. In MD simulations of two kinds of 
GPCRs of k-opioid receptor and rhodopsin in CHL-depleted and CHL-enriched model 
membranes, k-opioid receptor was suggested to functionalize better in CHL-enriched 
environments, while a relatively low concentration of CHL was favorable for 
rhodopsin.80 Therefore, GPCR function is closely linked to the composition of lipid 
membrane and CHL will highly affect the functional motion or conformational change of 
GPCRs.54,55,81-83  
In this study, MD simulations using the membrane models with different kind of 
lipid compositions showed the change in the ionic lock formation between Arg1313.50 and 
Glu2686.30 in apo-, epinephrine- and alprenolol-bound β2AR. We compared these results 
to the previous study performed using pure lipid bilayer POPE.47 The previous study 
showed that the ionic lock was formed in apo and inverse agonist carazolol bound β2AR. 
Our simulations with pure POPC and POPC/POPE/CHL/SM membranes were consistent 
with the previous study. Our simulation further suggested that the receptor in apo- and 
epinephrine- or alprenolol-bound form hardly maintained the ionic lock in POPC/CHL 
bilayer. This means that the composition of lipid membrane is essentially important for 
the activation of GPCR. One of the lipid components; CHL, has been observed to 
strongly interact with the receptor in the POPC/CHL/GM1 and POPC/POPE/CHL/SM 
mixed membrane. The present computational study will clarify the complex structure of 
GPCR and CHL and enhance the understanding of the influence on the receptor function.  
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II.2 Methods 
The initial structure of β2AR receptor for MD simulations was taken from an X-
ray crystal structure of the carazolol-bound β2AR/T4-lysozyme fusion protein (code 
2RH1) solved by Cherezov, et al..84 The lysozyme and ligand carazolol were removed. 
The N-terminal 35 residues did not appear in the crystal structure. Hence, the missing 
residues were not included in our model of β2AR receptor. The protonation states of 
charged residues and histidines were determined on the basis of pKa values calculated by 
PROPKA.85 According to the PROPKA calculation results, the δ nitrogen atoms in 
His93, 172, 178, 269 and 296 were set to be protonated and the ɛ nitrogen atoms were 
deprotonated for those residues. 
The full agonist epinephrine was manually docked into the β2AR and the neutral 
antagonist alprenolol was also docked to the β2AR, referring the crystal structure of 
ligand-bound β2AR (PDB code 3NYA).
50 The chemical structures were subjected to 
geometrical optimization at the B3LYP/6-31 G** level using Gaussian03 software. 
Atomic charges of the chemicals were determined by the restrained electrostatic potential 
(RESP) fitting procedure86 using the optimized structure. The force field parameters for 
epinephrine and alprenolol were determined by parameterizing fragment molecules and 
combining them according to the CHARMM parameterization methodology. The 
CHARMM force field for small organic molecules24 and the CHARMM27 force fields 
for lipids87 were employed for all simulation. All of the bilayer models were constructed 
using VMD ver. 1.888 and an in-house program named GLYMM which is a VMD plug-in 
to add a function of automatically making a heterogeneous lipid bilayer.57 Initially, the 
coordinates of all lipids were generated by the membrane tool of VMD, which provided 
the atom geometry of the liquid crystalline state of POPC lipids. Next, some of POPC 
molecules were converted into POPE, SM, CHL, or GM1 by GLYMM. The missing 
parameters were already created based on the analogy with available parameters.89 The 
POPC bilayer model consisted of 226 POPC molecules. The POPC/CHL bilayer 
consisted of 120 POPC and 112 CHL molecules (POPC/CHL = 0.52:0.48). The 
POPC/CHL/GM1 bilayer consisted of 128 POPC, 104 CHL and 7 GM1 molecules 
(POPC/CHL/GM1 = 0.54:0.43:0.03). The POPC/POPE/SM/CHL bilayer consisted of 36 
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POPC, 58 POPE, 112 CHL and 26 SM molecules (POPC/POPE/CHL/SM = 
0.15:0.25:0.48:0.12). Hence, calculation models in this work provided various types of 
membrane environments in which β2AR receptor were placed. TIP3P water molecules 
and ions to neutralize the calculation cell were generated to solvate the complex of β2AR 
and lipid membrane, making a periodic boundary box of ca. 80 Å × 90 Å × 120 Å. 
Consequently, the total number of atoms was approximately 75000 in each model as 
shown in Fig. 2.1(a).  
MD simulations were carried out for every model using NAMD ver. 2.725 under 
the NPT ensemble condition. The simulations were divided into four parts: minimization, 
heating, equilibration, and production runs. After the potential energy had been 
minimized, the model system was heated to 310 K with z coordinates of the head groups 
of the lipids restrained in order for the lipids to move only in the x and y directions. 
Gradually releasing the restraint, we equilibrated the system at a constant temperature of 
310 K and a constant pressure of 1 atm and then carried out production runs under no 
restraint condition. The simulation times for equilibration and production runs were 10 ns 
and 100 ns, respectively. Non-bonded interaction terms were computed with a cutoff 
distance of 12 Å, where a switching distance of 10 Å was applied to make the non-
bonded interaction zero at the cutoff distance smoothly. An integration time step was 2 fs. 
A periodic boundary condition was applied to all directions of the calculation cell, and 
the particle mesh Ewald method was employed to compute the long-distance non-bonded 
interaction. CHARMM27 force field87 was adopted for all the atoms except for ligand 
chemical. 
The root mean square deviation (RMSD) measurement was performed, using the 
ptraj module of AMBER11.23 In this analysis, only the coordinates for C, O, and N atoms 
of the main chain of receptor were used, because the flexibility of the side chain is large. 
The trajectories acquired from the 100 ns MD simulation were fit to the snapshot 
structure after the 10 ns equilibration run as a reference. The average structure was 
calculated using the trajectories for the last 20 ns, because the RMSD showed small 
values for the last 20 ns in MD simulation.   
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Fluctuation of main chain atoms for the respective residues of the receptor was 
examined using the trajectories for 100 ns of the MD simulation. Fluctuation was 
evaluated by the B-factor values90 calculated by the ptraj module of AMBER11 without 
including side chain. The structure after equilibration was used as the reference, and the 
trajectories were fit to this reference with respect to C, O, and N atoms in the main chain 
to eliminate the movement due to the rotation and the transversal motions.  
The Cα-Cα and N-O distances shown in Fig. 2.7 were computed from the snapshot 
structures of the 100 ns MD simulation. We focused on two major conformational 
changes in which one is the inactive; ionic lock is formed, and another is the active state; 
ionic lock is broken, as shown in Fig. 2.1(c). The N-O and Cα-Cα distances regarding to 
the ionic lock were measured to examine whether the ionic lock is formed or broken 
between the intracellular ends of helix3; Arg131, and helix6; Glu268. Another distance 
between Lys267 of intracellular ends of helix6 and Asp331 of intracellular ends of helix7 
was also measured with respect to Cα-Cα and N-O distances as shown in Fig. 2.1(d).  
The distribution of lipid molecules around β2AR was measured with respect to 
their distance and direction and was visualized using gnuplot. Each coordinate of lipid 
molecule in the respective trajectories was rotated and superimposed so that β2AR were 
fitted to the reference one. 
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Figure 2.1 Computational model of lipid membrane with protein and ligand. 
(a) Computational model of β2AR embedded in a lipid membrane with water layer. (b) Conformation of 
seven transmembrane helices of β2AR extracted from crystal structure; PDB code: 2RH1. (c) Intracellular 
ends of helix3 and helix6. The structure keeping the ionic lock is shown in green and that without 
maintaining the ionic lock is in cyan. (d) Intracellular ends of helix6 and helix7. The side chains of 
Lys2676.29 and Asp3317.58 in the agonist-bound state is colored green and that of the antagonist-bound state 
is cyan.  Structures of (e) agonist epinephrine and (f) antagonist alprenolol.  
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II.3 Results  
We carried out 12 patterns of 100 ns MD simulations for β2AR embedded in pure 
and/or mixed membrane bilayers as shown in Table 2.1. The crystal structure of β2AR; 
PDB code: 2RH1, shown in Fig. 2.1(b) was used for the receptor. For the ligand-free, apo 
form, the simulations are labeled as a, b, c and d. An agonist epinephrine (Fig. 2.1(e)) 
was docked into the binding pocket manually referring to the literature,91,92 and the 
simulations are labeled as a', b', c' and d'. An antagonist alprenolol (Fig. 2.1(f)) was 
placed at the binding site, referring the crystal structure; PDB code: 3NYA,50 and the 
simulations are labeled as a", b", c" and d". The simulations using pure POPC bilayer 
were labeled as a, a' and a". POPC bilayer containing CHL was used in simulations b, b' 
and b". POPC, CHL and GM1-ganglioside containing membrane was used in simulations 
c, c' and c". The mixed membrane consisting of POPC, POPE, CHL and SM was used in 
simulations d, d' and d". 
Table 2.1: Calculation pattern of the MD simulations 
Simulation Components of Lipid Bilayer Protein Ligand Simulation time (ns) 
a POPC β2AR -- 100 
a' POPC β2AR Epinephrine 100 
a" POPC β2AR Alprenolol 100 
b POPC/CHL β2AR -- 100 
b' POPC/CHL β2AR Epinephrine 100 
b" POPC/CHL β2AR Alprenolol 100 
c POPC/CHL/GM1 β2AR -- 100 
c' POPC/CHL/GM1 β2AR Epinephrine 100 
c" POPC/CHL/GM1 β2AR Alprenolol 100 
d POPC/POPE/SSM/CHL β2AR -- 100 
d' POPC/POPE/SSM/CHL β2AR Epinephrine 100 
d" POPC/POPE/SSM/CHL β2AR Alprenolol 100 
  
 
29 
II.3.1 Fluctuation of protein residues  
Fluctuation of protein structure is closely related to the stability of protein. 
Flexibility of protein was highly correlated with protein functions.93 B-factor analysis 
presents the deviation of atom positions from their average points. The calculated B-
factor values of β2AR for the respective models are shown in Fig. 2.2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 B-factor analyses 
B-factor values for all the residues of β2AR for apo, and agonist- or antagonist-bound states with 4 types of 
lipid bilayer membranes. B-factor values were obtained from the trajectories for100 ns in MD simulation. 
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A comparison among simulations a, a' and a" suggested that, in POPC bilayer, the 
flexibility of protein residues in apo form was higher than those in the presence of 
epinephrine and alprenolol, and simulation a" gave the smallest fluctuation (Fig. 2.3(a)). 
Therefore, alprenolol stabilized the β2AR structure. The flexibility of protein residues for 
POPC/CHL bilayer model was significantly decreased compared to that of pure POPC 
bilayer (Fig. 2.3(b)). Simulations for POPC/CHL/GM1 and mixed POPC/POPE/CHL/SM 
bilayers showed further small flexibility compared with the pure POPC and POPC/CHL 
bilayer (Figs. 2.3(c) and 2.3(d)). In the presence of alprenolol, simulations always 
showed the small flexibility for protein residues than other simulations.94 These results 
suggest that the lipid molecule strongly influences the stability of the residues and 
alprenolol also affects the flexibility of the receptor.   
 
 
 
 
 
 
 
Figure 2.3 Superimposition of B-factor values 
Superimposition of B-factor values for all residues of β2AR in apo form and the agonist- or the antagonist-
bound form. (a) pure POPC bilayer, (b) POPC/CHL bilayer, (c) POPC/CHL/GM1 bilayer, and (d) 
POPC/POPE/CHL/SM mixed bilayer. B-factor values were obtained from the trajectories of the 100 ns MD 
simulation. 
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II.3.2 Binding Structure 
Figures 2.6(a) and 2.6(b) show the superimposition of the average structures of 
simulations for epinephrine-bound and alprenolol-bound β2ARs to the apo-β2AR in the 
POPC/POPE/CHL/SM mixed membrane (simulations d, d' and d"). The averaged 
structures were obtained from the last 20 ns MD simulations (Fig. 2.4) and pymol 
software95 were employed to superimpose the structures with respect to main chain atoms 
of β2AR. β2AR is bound to Gα protein with making hydrogen-bond network between 
them, in which Thr682.39, Asp1303.49 and Arg1313.50 of β2AR are strongly involved in the 
binding.94 The comparison of β2AR structures among simulations d, d' and d" indicated 
that the Gα binding site kept the almost similar conformation as shown by blue mesh in 
Figs. 2.7(a) and 2.7(b). To analyzed the interactions between ligands and β2AR receptor 
in all the models (Figs. 2.5 and 2.6), we evaluated the hydrogen-bond network connecting 
ligand and β2AR. In the presence of epinephrine (Fig. 2.7(c), Figs. 2.5 and 2.6), 
epinephrine interacts with Ser2035.42, Ser2075.46 and with Asp1133.32 of β2AR. The 
movement of helix5, which has also been investigated in the recently published crystal 
structures of β2AR,
45,51,94 is important for forming the hydrogen-bond network between 
ligand and receptor. In case of alprenolol (Fig. 2.7(d), Figs. 2.5 and 2.6), it interacts with 
Asp1133.32 but no interaction with Ser2035.42 and Ser2075.46. Hence, the inverse agonist 
and/or antagonist will be not involved in the movement of helix5, which is compatible 
with the previous computational study.94 The interactions between ligand (epinephrine or 
alprenolol) and β2AR (Figs. 2.7(c) and 2.7(d)) indicated that a stable interaction 
maintained in the simulation.  
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Figure 2.4 Average structures for 12 models 
Comparison of β2AR structures. The average structures for the apo and the ligand-bound β2AR with 
different types of lipid bilayer, obtained from the last 30 ns MD simulation. The interaction domain with 
Gα protein is shown by blue mesh.  
  
 
33 
(a') POPC-EPI (a") POPC-ALP
(b') POPC/CHL-EPI (b") POPC/CHL-ALP
(c') POPC/CHL/GM1-EPI (c") POPC/CHL/GM1-ALP
(d') POPC/POPECHL/SM-EPI (d") POPC/POPE/CHL/SM-ALP
D1133.32
Y3167.43
N3127.39
N2936.55
S2035.42
S2075.46
2.9 Å
D1133.32
Y3167.43
N3127.39
N2936.55
S2035.42
S2075.46
2.5 Å
D1133.32
Y3167.43
N3127.39
N2936.55
S2035.42
S2075.46
3.3 Å
D1133.32Y316
7.43
N3127.39
N2936.55
S2035.42
S2075.46
4.2 Å
S2035.42
S2075.46
D1133.32
N2936.55
Y3087.35
W2866.48
3.1 Å
2.9 Å
2.6 Å
4.8 Å
S2035.42
S2075.46
D1133.32
N2936.55
Y3087.35
W2866.48
2.4 Å
2.0 Å
1.6 Å
S2035.42
S2075.46
D1133.32
N2936.55
Y3087.35
W2866.48
3.7 Å
3.1 Å
S2035.42
S2075.46
D1133.32
N2936.55
Y3087.35
W2866.48
2.6 Å
2.8 Å
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Ligand binding site 
Close view of the ligand binding site of β2AR. 
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Figure 2.6 protein ligand distance 
Protein ligand distance between the side chain residues of Asp1133.32, Ser2035.42 and Ser2075.46 of β2AR 
receptor and agonist epinephrine or antagonist alprenolol. Asp1133.32-ligand (red), Ser2035.42-ligand (green) 
and Ser2075.46-ligand (cyan) distances were monitored for 100 ns of the MD simulation. 
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Figure 2.7 Superimposition of the average structure and ligand-bound β2AR 
(a), (b) Superimposition of the average structure of ligand-bound β2AR (cyan) on that of the apo one 
(green), obtained in the POPC/POPE/CHL/SM mixed membrane. The interaction domain with Gα protein 
is shown by blue mesh at the intracellular part of the receptor. (c), (d) Close view of the ligand, epinephrine 
or alprenolol binding site of β2AR in POPC/POPE/CHL/SM mixed bilayer. 
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II.3.3 Ionic lock formation 
It is important to examine the activation of β2AR in terms of the contribution of 
the intracellular amino acid residues to the formation of ionic lock (Fig. 2.8). The ionic 
lock was continuously formed in pure POPC and POPC/POPE/CHL/SM mixed 
membrane containing apo, and epinephrine- or alprenolol-bound β2ARs. In the 
simulations a, a', a" and d, d', d", β2AR maintained a formation of ionic lock and the 
intracellular ends of helix3 and helix6 made a close network with each other (Fig. 2.7). 
Arg1313.50 and Glu2686.30 interacted with each other via salt bridge during the MD 
simulation. In a β2AR crystal structure; PDB code: 2RH1, Cα-Cα and N-O distances of 
Arg1313.50 and Glu2686.30 were 11.2 Å and 9.9 Å respectively, but typical distances of the 
inactive rhodopsin structures were ~8.8 Å and ~2.8 Å. The Cα-Cα and N-O distances were 
~9.5 Å and ~3.0 Å throughout the 100 ns simulations in a-a" and d-d" (Fig. 2.8). Both of 
these simulations showed that the ionic lock was formed and helix3 and 6 were close to 
each other. The N-O distance in Fig. 2.8 shows two pairs of lines, one pair represents 
NH1 to OE1 and OE2 distances and another one represents NH2 to OE1 and OE2 
distances. The distances of the two lines in the respective pairs were observed to 
synchronize with each other. The side chain atoms of Arg1313.50 and Glu2686.30 
fluctuated during the simulation while they always maintained the formation of ionic 
lock. No noticeable difference was observed among apo, epinephrine- and alprenolol-
bound β2AR.  
The apo-, and epinephrine- or alprenolol-bound β2AR in POPC/CHL bilayer in 
simulations b, b' and b" showed the break of the ionic lock (Fig. 2.8). The ionic lock was 
broken frequently in these three simulations. The N-O distances show no clear separation 
in four lines. The displacements of the side chain atoms of Arg1313.50 and Glu2686.30 are 
large compared to the simulations with other type of lipid membrane. The apo-, and 
epinephrine- or alprenolol-bound β2ARs in the POPC/CHL/GM1 bilayer in simulations c, 
c' and c" showed the instability of the ionic lock (Fig. 2.8). The ionic lock distance was 
frequently enlarged compared with simulations a-a" and d-d". The present findings 
suggest that the ionic lock distance strongly depends on the lipid compositions. 
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Figure 2.8 Ionic lock distances 
Ionic lock distance in β2AR receptor. Cα-Cα (red) and N-O (NH1-OE1: blue; NH1-OE2: magenta; NH2-
OE1: cyan; NH2-OE2: brown) distances were measured for 100 ns in MD simulations. apo-β2AR and the 
agonist epinephrine- or the antagonist alprenolol-bound β2AR in pure POPC (a, a', a"), POPC/CHL/GM1 
(c, c', c") and POPC/POPE/CHL/SM (d, d', d") keep the ionic lock formation while the ionic lock is broken 
in POPC/CHL (b, b', b").  
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II.3.4 Characteristic conformational changes in the side chain residues 
The conformational change of side chain will affect on Gα protein bound with 
β2AR. Hence we analyzed the conformation of the side chains at the intracellular part of 
β2AR, especially for three residues Thr68
2.39, Asp1303.49 and Arg1313.50 that are involved 
in the binding to Gα protein. The conformations of these three residues are similar among 
all the models. The distances between two of these three residues are represented in Fig. 
2.9 and 2.10. The Cα-Cα and N-O distances give the almost similar kinds of results in 
apo-, and epinephrine- or alprenolol-bound β2AR in all models. We observed the Cα-Cα 
and N-O distances between Thr682.39 and Asp1303.49 in all simulations. The distances 
were ~7.5 Å and 3-6 Å in a-a", c-c" and d-d" (Fig. 2.9). In contrast, the distances of were 
~9.5 Å and 5-8.5 Å in the CHL bilayer simulations in b-b". We also evaluated the Cα-Cα 
and N-O distances between Thr682.39 and Arg1313.50 in all the simulations. The distances 
were ~8.5 Å and 4 Å in a-a", c-c" and d-d" (Fig. 2.10), but these distances were 9-10.5 Å 
and 4-6 Å in CHL containing membrane in b-b". These changes in distance are similar to 
Fig. 2.7. In contrast, Lys2676.29 of intracellular end of helix6 and Asp3317.58 of 
intracellular end of helix7 showed a different conformational change among all the 
models (Fig. 2.11). The distance between Lys2676.29 and Asp3317.58 was relatively short 
in apo- and alprenolol-bound β2AR in all models whereas the distances became long in 
the epinephrine-bound β2AR. Judging from these N-O distances, we concluded that the 
interaction was strongly maintained between Lys2676.29 and Asp3317.58 in a and a". In 
contrast, this interaction was often broken in a' for the epinephrine-bound β2AR. The N-O 
distance between Lys2676.29 and Asp3317.58 was occasionally maintained in b and b", c 
and c", d and d" and the interaction was almost broken in b', c' and d'. Therefore, the 
distance between Lys2676.29 and Asp3317.58 will be one of the important indces that varies 
depending on the presence and the absence of antagonist.  
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Figure 2.9 Distance between Thr68
2.39
 and Asp130
3.49
 
Distance between the side chain residues of Thr682.39 and Asp1303.49 at the intracellular part of β2AR 
receptor. Cα-Cα (red) and O-O (OG1-OD1: blue; OG1-OD2: magenta) distances were monitored for 100 
ns of the MD simulation. 
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Figure 2.10 Distance between Thr682.39 and Arg1313.50 
Distance between the side chain residues of Thr682.39 and Arg1313.50 on helix3 at the intracellular part in 
β2AR. Cα-Cα (red) and O-N (OG1-NH1: blue; OG1-NH2: magenta) distances were monitored for 100 ns 
of the MD simulation. 
  
 
41 
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
0 10 20 30 40 50 60 70 80 10090
Time (ns)
D
is
ta
n
c
e
 (
Å
)
12
10
8
6
4
2
0
16
14
(a) POPC (a') POPC-EPI (a") POPC-ALP
(b) POPC/CHL (b') POPC/CHL-EPI (b") POPC/CHL-ALP
(c) POPC/CHL/GM1 (c') POPC/CHL/GM1-EPI (c") POPC/CHL/GM1-ALP
(d) POPC/POPE/CHL/SM (d') POPC/POPE/CHL/SM-EPI (d") POPC/POPECHL/SM-ALP
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
D
is
ta
n
c
e
 (
Å
)
 
 
 
 
 
 
Figure 2.11 Distances between Lys267
6.29
 and Asp331
7.58
 
Distances between the side chain of Lys2676.29 and Asp3317.58 on helix7 at the intracellular part of β2AR. 
Cα-Cα (red) and N-O (NZ-OD1: blue; NZ-OD2: magenta) distances were monitored all through 100 ns of 
MD simulation.  
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II.3.5 Distribution of lipid molecules 
The distribution of lipid molecules were analyzed using the trajectories acquired 
from the last 30 ns MD simulation (Fig. 2.12). The lipid molecules, which are located 
near around β2AR, showed sharp distributions, whereas distributions became broad for 
the lipid molecules that are apart from β2AR. The sharpness in distribution will be due to 
the interaction between lipid molecules and β2AR. The lipid molecule, CHL, is found to 
be distributed heterogeneously in all the models (Fig. 2.12). Superimpositions of the 
distribution of lipid molecules in apo- and epinephrine- or alprenolol-β2AR for the 
respective membrane models are shown in Fig. 2.13. In case of POPC/POPE/CHL/SM 
mixed membrane, two CHLs marked by red circle always stay at the same position 
during last 30 ns MD simulations (Fig. 2.14(a)). This position is the location between the 
helix4 and helix5 of β2AR. Fig. 2.14(b) shows the top view of CHL distributions around 
β2AR and the CHLs colored red are bound to β2AR. CHL has a highly hydrophobic part. 
In the upper and lower leaflets of the lipid membrane, two CHLs mainly interact with the 
non-polar hydrophobic residues of Ala1985.37, Ala2025.41, Val2065.45, Pro1684.60, 
Ile2145.53, Val1263.45 and Val1293.48 (Fig. 2.14(c)). The CHL in the upper leaflet interacts 
with Ala1985.37, Ala2025.41, and Val2065.45 and Pro1684.60. The CHL in the lower leaflet 
interacts with Val2065.45, Ile2145.53 and Val1263.45, Val1293.48. Hence the hydrophobic 
interaction tightly connects CHL molecule to helix5 of β2AR.  
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Figure 2.12 Distribution of lipid molecules 
Distribution of the lipid molecules around β2AR receptor obtained from the trajectories for the last 30 ns of 
MD simulation. POPC (green), CHL (red), POPE (blue), GM1 (cyan) and SM (cyan) lipid molecules are 
depicted in their density shown at the side bar in unit of /nm2. 
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Figure 2.13 Superimposition of lipid molecules 
Distribution of lipid molecules, obtained by superimposing the illustrations for the respective lipid 
molecules in Fig. 2.12. A red circle indicates the CHL that always stays at a specific position during the last 
30 ns of MD simulation. 
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Figure 2.14 CHL distribution around GPCR  
(a) Distribution of the lipid molecules for POPC (green), POPE (blue), CHL (red) and SM (cyan). Red 
circle indicates the area that CHL molecules always stay during the last 30 ns of MD simulation. (b) Close 
view of CHL distribution around GPCR, in which the CHL colored red is always bound to GPCR. (c) 
Hydrophobic interaction between the CHL and GPCR in the upper and the lower leaflets of the lipid 
membrane.  
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II.4 Discussion 
Protein flexibility is closely related to the function of a protein. We have analyzed 
the residue fluctuation by B-factor analysis. The comparison of B-factor among the 
simulation models indicated that the flexibility of protein residues in apo form is higher 
than those in the presence of epinephrine and alprenolol. Protein residues give the 
smallest fluctuation in the presence of alprenolol, which suggests that alprenolol 
stabilizes the β2AR structure. Goetz, et al. carried out MD simulation on the agonist 
isoprenaline- or inverse agonist carazolol-bound β2AR.
94 Their comparison of B-factor 
between the isoprenaline- and the carazolol-bound β2ARs demonstrated that the residue 
fluctuation was reduced in the presence of carazolol, which is consistent with our results 
(Figs. 2 and 3).  
Some previous studies have revealed that the binding modes of epinephrine and 
alprenolol to β2AR were different.
50,51,96-98 In computational approaches, Simpson, et al. 
carried out MD simulation on the epinephrine-bound β2AR.
96 In their calculation the 
hydrogen-bond interactions with epinephrine were observed at Ser2035.42, Ser2075.46 and 
Asp1133.32, which is compatible with our results (Fig. 2.7(c), Figs. 2.5 and 2.6). An X-ray 
crystal analysis suggested the interaction of Ser2035.42 and Ser2075.46 with a ligand.51 In 
many computational studies on the structure of the agonist-bound and the inverse 
agonist/antagonist-bound β2ARs, an agonist was found to make hydrogen-bonds with 
receptor through the residues of Ser2035.42, Ser2075.46 and Asp1133.32.97,98 In contrast, the 
inverse agonist/antagonist bound to β2AR was shown to make the hydrogen-bond 
network with Asp1133.32 and not to establish the hydrogen-bonds with Ser2035.42 and 
Ser2075.46,50 which is also consistent with our results (Fig. 2.7(d), Figs. 2.5 and 2.6).  
The ionic lock formation of GPCR in lipid membrane has already been studied in 
simulation and suggested to play an important role in the activation of GPCR.47,99 About 
70% of GPCRs of the rhodopsin family contain the E(D)RY(W) motif on helix3. 
Arg1353.50 of the conserved motif makes an intrahelical salt bridge to the neighboring 
Glu1343.49. Arg1353.50 also interacts with Glu2476.30 strongly. Further, Glu2496.32 interacts 
with the backbone NH of Lys3117.58 at the kink from helix7 to the small cytoplasmic 
helix8. During the activation of rhodopsin, the interhelical interactions between 
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Arg1353.50 and Glu2476.30, and between Glu2496.32 and Lys3117.58 were observed to be 
broken.99 The disruption of the intrahelical salt bridge between Glu1343.49 and Arg1353.50 
at the cytoplasmic terminus of helix3 was proposed to be a key factor for the transition to 
the active conformation.47,99  
An important difference between the crystallographic structures of rhodopsin65-67 
and β2AR
46,49,84,100 bound with the partial inverse agonist carazolol and timolol is the  
disruption of the ionic lock. The β2AR structures lack the interhelical interactions 
between homologous residues Arg1313.50 and Glu2686.30, and between Lys2706.32 and 
Asp3317.58. Dror, et al. carried out MD simulation on a carazolol-bound β2AR embedded 
in pure POPE lipid bilayer.47 They showed that the Cα-Cα distance was below 9.5 Å for 
91% of the simulation time. According to their results, the ionic lock was stably 
maintained between the backbones of Arg1313.50 and Glu2686.30 for the inverse agonist 
bound β2AR. This finding is consistent with our results using the pure POPC bilayer. But 
the intrahelical salt bridge between two adjacent residues Asp1303.49 and Arg1313.50 
appear to be preserved and it stabilizes the inactivated form of the receptor. Furthermore, 
intracellular ends of helices 3 and 6 are substantially far apart from each other compared 
with those in rhodopsin.47 The disruption of the ionic lock was previously suggested to be 
the crucial step for the GPCR activation. Some mutagenesis studies indicated that the 
mutations of the residues related to the ionic lock in β2AR and those of homologous 
residues in rhodopsin-family GPCRs resulted in continuous receptor activation.70-72,99 In 
spite of the above suggestion, the ionic lock may be not only major factor in GPCR 
activation because β2AR has the broken ionic lock in the crystallographic structures. 
In the inactive state of β2AR, Lys270
6.32 and Asp3317.58 were suggested not to 
interact with each other in contrast to the interaction between the homologous residues; 
Glu2496.32 and Lys3117.58, in the inactive state of rhodopsin.99 In our results we found 
that another residue, Lys2676.29 kept an adequate distance to Asp3317.58 in apo- and 
alprenolol-bound β2AR in all calculation models. In the epinephrine-bound β2AR 
structures, this distance became noticeably larger in all models, which suggests the 
presence of a different kind of salt bridge in the inactive form of β2AR.  
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The transmembrane receptors are in contact with the membrane lipid bilayer, 
which suggests that membrane has an important influence on receptor structure and 
function.101 Hence, it is necessary to analyze the effect of lipid composition on the 
structural stability of the receptor. As well as other membrane proteins,54 the optimal 
function of GPCR will depend on the lipid environment. The significance of specific 
lipids in the function of GPCR has been demonstrated in a variety of studies.102,103 For 
example, the presence of phosphatidylethanolamine (PE) was shown to modulate the 
activation of GPCR.102 In addition, the presence of phospholipids with unsaturated fatty 
acids in the membrane is required for efficient signaling of rhodopsin.103 Similar to other 
lipid molecules, CHL is also required for the optimal function of membrane proteins.101 
The lipid-receptor interactions, especially CHL-receptor interaction, is involved in the 
modification of conformation and function of several GPCR family proteins.55 CHL is 
distributed heterogeneously in domains or pools of biological and artificial membranes104 
and believed to be important for the maintenance of membrane structure. CHL modulates 
the conformation and the function of membrane proteins by a direct molecular interaction 
with the receptor105 or due to the alteration of the membrane physical properties induced 
by the presence of CHL.101,106,107 For example, CHL is directly bound to the sterol 
regulatory element binding protein cleavage activating protein (SCAP), which is a large 
polytopic membrane protein, thereby CHL induces a conformational change in SCAP.  
The CHL-receptor interactions have extensively been studied in the case of 
rhodopsin. Due to the increase of the amount of CHL, rhodopsin shifted itself to the 
inactive conformation.108 Molecular dynamic simulation with rhodopsin in a membrane 
containing CHL and unsaturated phospholipids suggested the direct interaction between 
rhodopsin and CHL109 and hence the enhancement of the stability of the receptor in the 
membrane. Further, CHL is required for keeping a high binding affinity between ligand 
and receptor. For example, the efficiency of ligand binding to the cholecystokinin 
receptor was reported to be reduced by the lowering of the concentration of CHL in 
membrane.110 The importance of CHL in membrane for the ligand binding was also 
suggested in subtype 2 galanin (GalR2) and oxytocin receptor.111,112 Moreover, CHL-
receptor interaction was also found in case of β2AR. A recent X-ray crystal analysis 
suggested that CHL molecules were tightly bound to β2AR
100 and CHL seemed to be an 
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important component for crystallization of the receptor. These findings indicate that CHL 
composes a specific interaction with β2AR and promotes the enzymatic functions for 
ligand binding, receptor-G-protein interaction, and/or downstream signal transduction.1113 
Hanson, et al. provided the crystal structure of β2AR bound with both CHL and a partial 
inverse agonist timolol and showed that CHL was bound at a shallow surface groove 
formed by segments of helices 1, 2, 3, and 4.49 CHL was shown to enhance the thermal 
stability of β2AR, by forming many intermolecular interactions through van der Waals 
interactions or hydrogen bonding to β2AR helix. For example, Tyr70
2.41 makes the van 
der Waals interaction with ring A of CHL and a hydrogen bond to Arg1514.43 in β2AR.
49 
A recent study proposed a characteristic amino acid sequence, named as cholesterol 
recognition/interaction amino acid consensus (CRAC) motif, which is the dominant 
region interacting with CHL and observed in three representative GPCRs of rhodopsin, 
β2AR and serotonin1A receptor. β2AR presents CRAC motifs in transmembrane helix5; 
residues 231-221, and helix7; residues 324-328.114 In our molecular dynamics study, 
CHL-binding site was found in all the β2AR in apo- and epinephrine- or alprenolol-bound 
form and the contribution of CHL for β2AR stability was suggested. In our simulations 
except for pure POPC model, CHL appeared to be distributed heterogeneously in the 
membranes and a specific CHL-binding to the helices 3, 4 and 5 in β2AR was observed in 
the simulations c-d". CHL molecules mainly interact with the hydrophobic residues such 
as Ala1985.37, Ala2025.41, Val2065.45 and Ile2145.53, with its principle molecular axis 
almost parallel to the membrane normal direction. 
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II.5 Conclusion  
The influence of the lipid composition on the structural conformation of one kind 
of GPCR protein, β2AR, was investigated by performing molecular dynamics 
simulations. Four types of lipid membranes, pure POPC, POPC/CHL, POPC/CHL/GM1 
and POPC/POPE/CHL/SM containing three kinds of β2AR; apo- and the agonist 
epinephrine- or the antagonist alprenolol-bound form, were employed for 100 ns 
simulation and the computational results were compared. This work presented the 
following findings. (1) The stability of the ionic lock formation between Arg1313.50 and 
Glu2686.30 varies depending on the difference of the lipid component of membrane. (2) 
The side chain interaction between Lys2676.29 and Asp3317.58 became strong in apo- and 
the alprenolol-bound β2AR, compared with the epinephrine-bound β2AR in pure POPC 
membrane. (3) A strong hydrophobic interaction was observed between CHL and the 
receptor at the transmembrane helix5 in POPC/CHL/GM1 and POPC/POPE/CHL/SM 
membranes. CHL is specifically bound at the position between helix4 and helix5 in 
β2AR.  
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Chapter III 
Computational analysis on the binding of epitope 
peptide to human leukocyte antigen class I molecule 
A*2402 subtype 
Abstract  
Immunological response induced by small amino peptide has attracted much 
recent attention in the field of immunotherapy. Wilms’ tumor WT1 protein is one of the 
potent tumor antigens inducing immunological response in mouse and human, because 
WT1 is over expressed in many types of leukemia and various kinds of solid tumors. A 9-
mer peptide encoded in WT1 protein (CMTWNQMNL; amino acid 235–243) is known 
to serve as antigenic peptide for human leukocyte antigen (HLA)-A*2402 molecule. It 
was reported that the replacement of the second amino residue, which is deeply 
responsible for the peptide binding to HLA, induced strong immunological response 
compared to the natural peptide. In this study, 19 kinds of single amino substitutions were 
introduced at position 2 of this 9-mer WT1 peptide. We performed molecular dynamics 
simulation on the complex of each of WT1 epitope peptides and HLA-β2m molecule, and 
subsequently estimated the binding affinity using molecular mechanics/generalized-Born 
surface area method combined with normal mode analysis. Our computation indicated 
that the peptide containing M2Y or M2W mutation showed high binding affinity to the 
HLA-β2m molecule as well as the natural peptide. We have also examined the role of the 
residue at position 2 in peptide binding to HLA-β2m. The calculation showed that van 
der Waals interaction between the side chain of the residue at position 2 and hydrophobic 
residues inside B-pocket of HLA are important. These findings will be helpful to search 
other potent peptides that will enhance strong immunological response specific to HLA–
A*2402 molecule.  
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 III.1 Introduction 
Major histocompatibility complex (MHC) is a transmembrane glycoprotein that 
plays an important role in immunological system. Human MHC molecule is usually 
called as human leukocyte antigen (HLA) and HLA molecules are grouped into class Ι 
and ΙΙ. MHC class I molecule is a heterodimer of heavy chain called α chain, whose 
mass-weight is 45 kDa, and light chain called β2 micro globulin (β2m) with a mass-
weight of 12 kDa. A complex of an HLA and a peptide derived from antigen is displayed 
on the surface of nucleated cell or platelet. HLA heavy chain has a quite large diversity 
and thousands of genes have been detected so far, and the number of known genes for 
HLA heavy chain is still increasing. Each individual has two or three kinds of HLA out 
of several thousands of HLA genes.  
Viral protein or cancer-related antigens are detected as foreign molecules in a cell 
and dissociated by proteasome into peptide fragments consisting of 6-15 amino 
residues.115 This peptide fragment is bound to HLA class I molecule and the complex is 
carried to the cell surface in antigen display cells. Cytotoxic T lymphocytes (CTL) 
expressing T cell receptor recognize the complex, which results in inducing the 
immunological response to attack the virus-infected or oncogenic cells to exclude virus or 
tumor.116 
Immunological response has attracted much recent attention because of its 
potential for immunotherapy. At present, several peptides are assumed to be effective for 
medical treatment of cancer, leukemia, hepatitis C, and applied to patients in a clinical 
trial as vaccine through the controlled vaccination.117-119 This peptide-vaccine therapy is 
expected to lead the regression of disease-related cells without damaging normal tissues. 
Since the combination of HLA genes has a large diversity, the selection of peptide 
adequate for each individual is one of the important issues to enhance the performance of 
immunotherapy.  
The discovery of a peptide inducing strong immunological response is a key 
factor in immunotherapy. Since the peptide firmly bound to HLA molecule will be 
effective as medical material, the search of potent peptide, usually called as epitope, is 
  
 
55 
critically important. In this study, we focus on WT1 protein.120 WT1 protein is encoded 
in β2 Wilm’s tumor gene and overexpressed in leukemic and solid tumor cell. A 9-mer 
amino acid peptide encoded in WT1 protein was already known to work as an antigenic 
peptide for HLA-A*2402 molecule. Oka and his co-workers reported the experimental 
findings that the replacement of the second amino acid residue, which is considered to be 
deeply responsible for the peptide binding to HLA-A*2402, induced strong 
immunological response of WT1 specific CTLs compared to the natural peptide. A 
peptide containing a single amino residue mutation is currently applies for the clinical 
trial for a vaccination against solid tumor or leukemia.121  
Computer simulation enables us to visualize the interaction of proteins or the 
interaction of a chemical compound and its target protein. MD simulation is one of the 
major computational approaches for analyzing the interaction between epitope peptide 
and HLA molecules to predict a suitable epitope inducing immunological response. The 
feasibility of MD simulation was examined through a comparison with experimental 
methods.122,123 In this work, we employed molecular dynamics (MD) simulation to 
analyze the interaction between HLA molecule and epitope peptide. Atoms in the 
molecules are described as charged particles, and motions of the respective particles can 
be predicted in a time-evolution manner with calculating the forces among charged 
particles. Hence MD simulation produces a virtual system in which physiological 
conditions such as temperature and pressure are set equal to the designated experimental 
setup.  
We also performed computational analysis for estimating the binding affinity 
between epitope peptide and HLA-β2m heterodimer. Several computer programs to 
predict the binding affinity of peptides to HLA were already released so far. MHCpred124 
and PepDict125 are well known programs for HLA-peptide prediction. Those programs 
were developed on the knowledge-based approach or the neural network method making 
use of in vitro experimental data. These programs effectively and accurately predict the 
peptide binding with respect to the known kinds of HLAs. However, the accuracy of the 
prediction is insufficient for variety kinds of HLAs, especially for the HLA of which little 
experimental data are available. In this study, we carried out molecular dynamics 
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simulation, followed by molecular mechanics generalized Born/surface area (MM-
GB/SA) method and normal mode analysis.126 MD simulation provides a stable 
molecular structure of a complex of HLA-β2m heterodimer and epitope peptide. MM-
GB/SA method and normal mode analysis gives the binding free energy of the peptide to 
HLA, which directly corresponds to the binding affinity. The present computation is not 
knowledge-based approach and then requires no experimental data. Hence, the 
calculation method employed in this study will be applied to not only to major HLAs but 
also rare HLA molecules. 
In the first step of this study, we built calculation models for a complex of HLA-
A*2402 and WT1-derived epitope peptide; CMTWNQMNL, and also a complex of 
HLA-A*2402 and every kind of single amino residue-mutated peptides. MD simulation 
was applied to these complex models to analyze the binding structure and to estimate the 
binding free energy. Simulation showed a difference in binding free energy between the 
natural peptide and the mutated ones. The discussion was developed in terms of 
compatibility with the experimentally measured immunological response. Since the 
second residue at N-terminus of epitope (p2) is important for the peptide binding, the 
interactions of p2 residue with amino residues in HLA molecule will be closely 
investigated. This investigation will be helpful for designing the epitope peptide 
enhancing the binding to HLA molecules.     
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III.2 Methods 
III.2.1 Build of simulation model 
A structure of HLA-A*2402 was already resolved by an X-ray crystallographic 
analysis and registered in protein data bank127 in a complex form with an antigen peptide; 
PDB code 2BCK, in a resolution of 2.80 Å.128 This crystal structure contains two pairs of 
HLA-β2m complexed with epitope peptides, sulfate ions, glycerols, and waters. One of 
the HLA-β2m-epitope complexes was selected as a reference. Then, computational 
model was built by homology modeling. Modeller9.2 was employed for homology 
modeling,129-131 in which the original epitope peptide in the crystal structure was replaced 
by WT1 peptide. Further, p2 residue was converting from methionine of the natural 
peptide into other kinds of amino acids. The complex was solvated with about 5,000 
TIP3P waters,132 generated in a rectangular box using leap module of AMBER9133,134 in a 
manner shown in Fig. 3.1(a). 
 
III.2.2 Computational procedure 
MD simulation was carried out using sander module of AMBER9 program 
package.134 AMBER ff03 force field was employed. MD simulation was executed in 
three steps of minimization, heating and equilibration. Atom geometry was energetically 
minimized in the first step. The minimization was performed with the steepest descent 
method135 for the earlier 3,000 cycles and with the conjugated gradient method for the 
later 10,000 cycles, with only water molecules allowed to move freely. The minimization 
was executed in a similar manner, with water molecules and epitope peptides allowed to 
move. Again the minimization was executed without any constraint for waters, peptide 
and HLA-β2m. The heating calculation was executed in the NVT ensemble condition. 
The temperature of the model system was elevated from 0 K to 310 K for 200 ps. The 
equilibration calculation was performed in the NPT ensemble condition with a 
temperature of 310 K and a pressure of 1 atm. Langevin dynamics method was applied 
for controlling temperature and pressure with a collision frequency of 0.1 ps-1.136-138 The 
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long-distance electrostatic and van der Waals interaction was calculated under the 
periodic boundary condition, setting the cutoff distance to be 12 Å. The expansion and 
shrinkage of all covalent bonds connecting to hydrogen atoms were constraint with 
SHAKE algorithm.139 The integration time step was 2 fs. 6 ns equilibration calculation 
was carried out for all models.  
 
III.2.3 Estimation of binding affinity 
The binding affinity of HLA-A*2402-β2m and epitope peptide was estimated 
from the binding free energy ∆Gbind,
140 
∆Gbind = ∆Hbind - T∆Sbind 
 in which the enthalpic and entropic terms were computed by MM-GB/SA method141 and 
normal mode analysis126 respectively. 
500 snapshot structures were extracted from the trajectory of the last 1 ns run of 
the equilibrating MD simulation. For every snapshot structure, binding enthalpy was 
calculated by MM-GB/SA method and the average value of the binding enthalpy was 
obtained. 10 snapshot structures were extracted from the last 1 ns trajectory of MD 
simulation to calculate entropic term with the normal mode analysis and the averaged 
value was obtained for the entropic term. In the calculation of enthalpic term, the 
respective model structures for HLA-β2m, epitope peptide, and HLA-β2m-peptide 
complex were built from each of 500 snapshot structures, and ∆Hbind was computed with 
the following equation. 
                           ∆Hbind = Hcomplex – (HHLA-ß2m + Hpeptide) 
where ∆HHLA-ß2m, ∆Hpeptide, and ∆Hcomplex represent the free energies of HLA-β2m, 
epitope peptide and their complex, respectively. In the normal mode analysis, the entropy 
for rotation and vibration was computed using the models for HLA-β2m, epitope peptide, 
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and their complex and the change in entropy due to peptide binding was obtained from 
the following equation.  
                            T∆Sbind = TScomplex – (TSHLA-ß2m + TSpeptide) 
In this study, we introduced the deformation effect of epitope peptides due to 
binding to HLA. The ligand molecule in this work is a 9-mer peptide chain. The peptide 
chain has a large conformational diversity due to the rotation around the covalent bond. 
That is, 9-mer peptide shows a considerably large difference in structure between the 
HLA-bound and unbound states. This is a marked difference from low mass-weight 
compounds like medical drugs. In the usual MM-GB/SA method, the structure of ligand 
is assumed to be identical between the receptor-bound and unbound states. However the 
estimation of enthalpic and entropic component is not accurate if the diversity in 
configuration of the ligand molecule is large. The deformation effect should be taken into 
account to improve the energy estimation. In order to incorporate the deformation effect, 
additional MD simulations were performed for the model representing epitope peptide 
only, followed by evaluation of the binding free energy with MM-GB/SA method and 
normal mode analysis. The epitope peptide was placed in a rectangular box and solvated 
with about 5,000 water molecules. The cutoff distance for electrostatic and van der Waals 
forces was set to 12 Å. Totally 6 ns MD simulation was performed for equilibration and 
the trajectory for the last 1 ns was used for estimating the binding energy. Snapshot 
structures were extracted every 10 ps from the last 1 ns MD simulation and 100 structures 
were collected. MM-GB/SA method and normal mode analysis were executed to 
compute the enthalpic and entropic contributions.  The modified binding free energy was 
obtained from the following equations,   
∆Gmod = ∆Hmod - T∆Smod 
∆Hmod = Hcomplex – (HHLA + H´peptide ) 
T∆Smod = TScomplex – (TSHLA + TS´peptide ) 
where H´peptide and TS´peptide were calculated from MD simulation for epitope peptide 
only. 
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In order to examine the interaction between the side chain of p2 residue of epitope  
peptide and all the residues of HLA molecule, alanine-scanning calculation142,143 was 
performed, in which alanine was substituted for the amino acid at the residue of which 
the interaction energy with p2 residue was estimated. Comparison in energy between 
substituted and non-substituted models indicated the contribution of the residue to the 
total binding energy. The binding free energies between p2 residue and the residues of 
HLA were calculated by MM-GB/SA method.141 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Structure of HLA class I molecule and peptide.  
(a) Structure of HLA class I molecule combined with 9-mer peptide. 9-mer peptide is shown in the red stick 
representation, β2 microglobin is colored magenta. 9-mer peptide and HLA complex was solvated with 
about 5,000 of TIP3P waters, generated in a rectangular box for molecular dynamics simulation. (b) 
Structure of binding pockets of HLA class I molecule. This molecule has six binding pockets labeled A-F. 
The binding of an epitope peptide into the pockets will stabilize the complex. 
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III.3 Results and discussion 
III.3.1 Binding structure of epitope peptide to HLA class I molecule 
HLA class I molecule has six binding pockets labeled A-F as shown in Fig. 
3.1(b). The binding of epitope peptide to the pockets will stabilize the complex 
structure.128,144 The amino acid residue of the peptide playing an important role in binding 
to HLA-β2m is called “anchor residue”. The position of anchor residue and the location 
of significantly important pocket vary depending on the type of HLA. The second residue 
from N-terminus; p2, and the ninth residue; p9, are the anchor residues for HLA-A*2402. 
The favorable amino acid for anchor residue is also changed, depending on the type of 
HLA. For example Tyr or Phe at p2 residue makes the peptide binding strong in HLA-
A*2402,128 while Leu or Met generates a firm binding to HLA-A*2402.145 According to 
the experiment by Tsuboi, et al.,121 the substitution of Tyr for Met at p2 anchor residue 
makes the binding of WT1 peptide stronger. The residues responsible for the peptide 
binding to HLA are supposed to have little influence on the association with CTL. 
Therefore, the replacement of anchor residue with other kind of amino acids will be one 
of the effective approaches to enhance the binding of epitope peptide to HLA. In this 
study, the binding affinity was examined with changing the amino acid at p2 anchor 
residue of the natural WT1 peptide.     
Snapshot structures for analyzing binding mode and binding affinity were 
extracted from the last 1 ns trajectory of MD simulation. The model system should be 
sufficiently equilibrated for the sake of reliable analysis. One of the standard techniques 
to confirm the equilibration is to measure the root mean square deviation (RMSD) value 
between the snapshot structure at the time point concerned and the structure at the 
starting point. If the time evolution of RMSD shows constant, the system fluctuates in a 
single conformation and is confirmed to be equilibrated. Figure 3.2 shows RMSD value 
during MD simulation was monitored on the HLA-β2m peptide complex, with respect to 
the Cα, N, and C main chain atoms, setting the snapshot structure after heating 
calculation as a reference at the starting point. The RMSD plot indicates that RMSD 
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value fluctuates in a range of 2.8±0.5 Å for the last 1ns. This result means that the model 
system was in equilibration.   
 
 
 
 
 
 
 
 
Figure 3.2 RMSD for MD simulation 
RMSD for MD simulation on the HLA-β2m-peptide complex, computed with respect to the Cα, N, and C 
main chain atoms. The RMSD curves are presented only for natural peptide and M2Y mutant for the sake 
of visual clarity. 
 
Principal component analysis31,32 is another method to confirm the equilibration 
of the calculation system. Since protein usually fluctuates and has several probable 
confirmations, there exist several minimum points in potential energy surface. If the 
energy barrier separating potential minima is low enough, the structure fluctuates among 
some energetically minimized points during MD simulation. When the model system is 
in equilibration, the structure fluctuates only around a stable minimum point. Figure 3.3 
shows the results of principle component analysis was executed for the calculations on 
the natural peptide and 19 mutants. In every case, there appear several clusters, and the 
conformation converges to a single cluster with the progress of MD simulation. This 
result suggests that 6 ns MD simulation leads structural equilibration for the HLA-β2m-
peptide complex.  
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NP M2Y M2W M2V 
M2S M2R M2I M2L 
M2A M2F M2G M2P 
M2T M2C M2N M2Q 
M2K M2H M2D M2E 
 
 
 
Figure 3.3 Principal component analysis 
Principal component analysis for the natural peptide and 19 variants for 6 ns MD simulation (red represents 
the simulation for 0-2 ns, green for 2-4 ns and blue for 4-6 ns). 
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III.3.2 Binding free energy 
Table 3.1 shows the comparison of the calculated binding free energy, and the 
binding constant obtained from experiment for HLA-A*2402 bound with the natural 
peptide and M2Y variant. The binding constant Kd in Table 3.1 was measured in the in 
vitro experiment using flow cytometry by Oka, et al.121,146 According to their in vitro 
experiment, Kd value for the natural peptide was measured to be 1.82x10-5 M and that for 
M2Y variant was 6.40x10-7 M. Hence, M2Y showed a higher binding affinity to HLA-
A*2402, compared to the natural peptide. The calculation of binding free energy without 
deformation effect, ∆Gbind, indicated that M2Y mutant is more stable than the natural 
peptide. Accordingly, the usual technique for calculating binding free energy could 
predict the binding affinity measured in experiments. ∆Gmod of Table 3.1 shows a 
comparison in energy between the natural peptide and M2Y variant obtained with the 
deformation effect of epitope peptide took into account. The energy comparison shows 
that the binding of M2Y peptide is more stable than the natural peptide, which is also 
compatible with the experimental findings. The energy difference estimated from the 
binding constant is -2.0 kcal/mol between the natural peptide and M2Y. The calculated 
energy difference is -0.9 kcal/mol. Accordingly the combination of MM-GB/SA method 
and normal mode analysis with considering the deformation effect will correctly predict 
the binding affinity of epitope peptide bound to HLA-β2m. The result suggests that the 
deformation effect has a certain degree of importance in the prediction of the binding free 
energy.  
It is informative to clarify what chemical structure increases the binding affinity 
between HLA-β2m and epitope peptide. Hence, the p2 amino residue of the peptide was 
replaced with another kind of amino acids. The complex models for 19 kinds of variants 
bound to HLA-β2m were built and MD simulations were performed for all models, 
followed by free energy calculation with MM-GB/SA method and normal mode analysis. 
Our concern is how we can improve the binding affinity replacing an amino acid with 
another one to increase the electrostatic or van der Waals interaction. Tyr and Trp have 
aromatic ring and contain polar atoms possible for hydrogen bonding. Non-polar amino 
acid residues, Val, Leu, Ile, Phe, Pro, were substituted at p2 anchor position, because they 
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have large hydrophobic side chain to increase van der Waals interaction. Ser and Thr 
have hydroxy group in their side chains to make it possible to form hydrogen bonds. Cys, 
Asn and Gln can also make hydrogen bonds because of the presence of polar hydrogen 
atoms in their side chains. Basic polar amino acid residues, His, Lys, Arg, and acidic 
polar amino acid ones, Asp, Glu, can generate ionic interaction while hydrophobic 
interaction is little. Non-polar amino acid residues, Gly, Ala, have small side chains, but 
may contribute to keep peptide flexibility.  
 
Table 3.1: Comparison of the calculated binding free energy and the experimentally measured binding constant 
peptide A sequence Kd (M) ∆Gexp(kcal/mol) ∆Gbind(kcal/mol) ∆Gmod(kcal/mol) 
NP CMTWNQMNL 1.82x10-5  -59.6 -44.8 
M2Y CYTWNQMNL 6.40x10-7 -2.0 -64.4 -45.7 
Abbreviation: NP, natural peptide 
Underlined capital letter indicates anchor position; bold capital letter indicates a substituted amino acid 
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Table 3.2 shows the calculated binding free energy for the natural and other 19 
kinds of  peptide complexed with HLA-A*2402 molecules. The energy difference in 
∆Gmod indicates that all of substitutions except for M2Y and M2W are less stable than the 
natural peptide. ∆Hmod in the table also indicates that HLA-β2m complexed with M2Y or 
M2W mutant show the lowest energy among all the complexes. Namely these epitope 
peptides will give the highest binding affinity. It is already known that a modified 9-mer 
WT1 (M2Y) peptide showed much higher HLA-A*2402-binding affinity than the natural 
9-mer WT1 peptide.121 In this study, we found that the binding free energy of M2W to 
HLA-β2m is slightly lower than M2Y (-2.5 kcal/mol). This means that M2W peptide 
substitution is the most favorable in terms of binding affinity. The van der Waals energy 
(∆Hvdw) shows a favorable contribution to the peptide binding. ∆Hvdw value of the HLA-
β2m complexed with M2Y or M2W is the lowest among the complexes. The van der 
Waals energy of M2W is slightly lower then M2Y (-0.03 kcal/mol). Therefore M2W 
peptide substitution is more favorable because of the presence of large hydrophobic side 
chain. Among the other peptides M2K shows the highest ∆Hvdw value and highest 
binding free energy ∆Gmod, which suggests that the presence of Lys causes a strong 
instability for the binding of HLA-β2m and peptide. The large change in ∆Gmod in Table 
3.2 clearly demonstrates that the side chain of the anchor residue, p2, plays a quite 
important role for peptide binding. M2C, M2Q, M2S and M2P show the binding energies 
near to the natural peptide, which suggests that side chain hydrogen-bond doner or 
acceptor can serve as an anchor for peptide binding. Judging from the binding energy, 
M2H, M2I, M2T, M2G, M2N, M2A and M2E are not so stable. Further, M2V, M2F, 
M2L, M2D and M2R hardly maintain the stability of peptide binding.  
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Table 3.2: Calculated binding free energy for every kind of peptides with HLA 
peptide 
∆Hele 
(kcal/mol) 
∆Hvwd 
(kcal/mol) 
∆Hint 
(kcal/mol) 
∆Hsol 
(kcal/mol) 
∆Hmod 
(kcal/mol) 
T∆Smod 
(kcal/mol) 
∆Gmod 
(kcal/mol) 
NP -139.8 -89.0 6.4 144.2 -78.2 -33.4 -44.8 
M2Y -159.5 -93.4 10.0 157.4 -85.5 -39.8 -45.7 
M2W -190.8 -93.7 10.6 188.2 -85.7 -37.7 -48.2 
M2V -153.0 -71.1 5.5 152.4 -66.2 -37.7 -28.5 
M2I -155.0 -75.0 5.1 152.4 -72.5 -32.2 -40.3 
M2L -148.6 -77.3 0.4 150.5 -75.0 -46.1 -28.9 
M2A -142.1 -71.2 2.4 147.0 -63.9 -31.6 -32.3 
M2F -101.3 -71.1 1.8 106.4 64.2 -39.2 -25.0 
M2G -152.9 -80.3 7.0 153.9 -72.3 -38.0 -34.3 
M2S -173.7 -74.9 2.2 167.4 -79.0 -37.5 -41.5 
M2T -177.0 -73.5 4.6 176.4 -69.5 -30.6 -38.9 
M2P -182.2 -84.7 8.1 180.1 -78.7 -37.4 -41.3 
M2C -185.0 -89.4 6.7 183.5 -84.2 -40.8 -43.5 
M2N -163.4 -84.6 6.1 165.2 -76.7 -43.4 -33.3 
M2Q -187.2 -83.7 6.0 182.7 -82.2 -38.7 -43.5 
M2H -157.8 -83.5 5.4 161.3 -74.6 -33.9 -40.7 
M2K -234.3 -65.9 3.5 239.1 -57.6 -39.0 -18.6 
M2R -257.7 -83.6 5.6 261.3 -74.3 -45.0 -29.3 
M2D -102.9 -79.9 -0.8 110.0 -73.6 -44.9 -28.7 
M2E -63.3 -77.6 5.0 71.5 -64.1 -32.4 -31.7 
Abbreviation: NP, natural peptide; ∆Hele, electrostatic energy; ∆Hvdw, van der Walls interaction; ∆Hint, internal 
energy from bond, angle and dihedral; ∆Hsol, solvation energy; ∆Hmod, modified averaging enthalpic energy; 
T∆Smod, modified averaging entopic energy; ∆Gmod, modified binding free energy.  
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III.3.3 Binding Structure 
Figure 3.4 shows the superimposition of the averaged structures of 19 kinds of 
peptide to the natural peptide bound to HLA-β2m. The averaged structure for the last 1ns 
MD simulation was obtained for the respective models, and pymol software94 was 
employed to superimpose the structure of the HLA-β2m-natural peptide complex on that 
of the p2-mutated one, with respect to main chain atoms of HLA. The N-terminal sides of 
the peptide main chain for M2A, M2F, M2K, M2E and M2D models are largely deviated 
from that of the natural peptide. These peptides showed the instability in binding to HLA-
β2m molecule in Table 3.2. The C-terminal side of the epitope peptide is largely deviated 
in M2D, M2A, M2N, M2G and M2K models from the natural peptide. This indicated that 
the C-terminal region of M2D, M2A, M2N, M2G and M2K peptides is loosely bound to 
HLA. Several X-ray crystal structures obtained for other types of HLA indicated that no 
significant deviation was observed for the three residues at the both terminal regions.147 
This suggests that central residues of the epitope peptide are mainly responsible for the 
activation of CTL and the terminal residues primarily contribute to the binding of epitope 
peptide to HLA. Both terminal regions of M2Y, M2W, M2C, M2Q, and M2S are 
compatible with that of the natural peptide. All these peptide show the low binding 
energy in Table 3.2 and the complexes with HLA are stable. 
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Figure 3.4 Superimposition of the average structures 
Superimposition of the average structure of 19 kinds of peptide variants on that of the natural peptide 
bound to HLA-β2m. The structure of the natural peptide complexed with HLA-β2m is colored green in 
superimposition. The position of each residue on the epitope peptide is shown in the figure at the left top 
for natural peptide (NP). 
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III.3.4 Contribution of amino residues of HLA to peptide binding  
The interaction energy between p2 anchor residue and the respective residues of 
HLA were calculated by alanine scanning technique.142,143 In the alanine scanning 
calculation, one of the residues of HLA is replaced by Ala and then the binding energy is 
calculated with the residue-replaced model. A comparison in binding free energy between 
the models with and without replacement indicates the contribution of the residue to the 
peptide binding. The energy contribution of p2 residue is computed by MM-GB/SA 
method. Figure 3.5 shows the results of alanine scanning calculation, in which low 
energy value means positive contribution of the residue to the interaction with p2 anchor 
residue. In all HLA-β2m-peptide models, Tyr7, Glu63, His70, Phe99, Ser9 are related to 
the interaction. The locations of these residues are displayed in Fig. 3.5 to clarify the 
relationship with p2 anchor residue. These residues were reported to be located at the 
deep bottom of B-pocket.144 A comparison among 20 graphs in Fig. 3.5 suggests that the 
interaction with Ser9 of HLA residue is only enhanced in M2Y (red circle in Fig. 3.5). 
M2Y generates a hydrogen bond with HLA, which makes the peptide binding stable. The 
interaction with Ser9 of HLA residue is also enhanced in M2W. The time ratio for 
keeping hydrogen bond within 3.5Å was calculated from the last 1 ns MD simulation. 
Ser9 keeps a hydrogen bond to M2Y for 74% of MD simulation time, while other models 
scarcely keep the hydrogen bond with Ser9.  The interaction with Phe99 is the highest in 
M2W. This large interaction will be attributed to the π-π interaction between the indole 
group of Trp at p2 anchor residue and the aromatic ring of Phe. As for M2Y, M2Q and 
M2N, the interaction with Phe99 is also higher compared with the natural peptide. In 
M2Q, M2S, M2T and M2V, the interaction with Glu63 was increased while other 
peptides scarcely showed the favorable energy gain in the interaction with Glu63. In 
M2Q, M2S, M2T and M2V, several residues of protein also show small degree of 
interaction with p2 residue.  
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Figure 3.5 Interaction energy of p2 residue 
Interaction energy of p2 residue of epitope peptide with the respective residues of HLA class I molecule. A 
comparison of the energy diagrams suggests that several residues concerning the interaction are common 
among the mutants but the interaction with Ser9 residue of HLA is only enhanced in M2Y. 
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Table 3.3 shows the respective components of the binding free energy between p2 
residue and HLA-β2m, where ∆Hele-p2, ∆Hvdw-p2, and ∆Hsol-p2 represent the electrostatic, 
van der Waals, and solvation energies, respectively. There are many hydrophobic 
residues at the inside of B binding pocket of HLA. This suggests that hydrophobic 
residues of epitope peptide play an important role in peptide binding, as seen in M2I, 
M2L, and M2F. ∆Hvdw-p2 of M2S and M2G is -3.0 and -3.6 kcal/mol, and they are the 
highest among 20 peptides. This result is reasonably explained from the smallness of the 
side chain of Gly and the hydrophilicity of Ser. In contrast, ∆Hvdw-p2 of M2W is -15.4 
kcal/mol, which is the lowest among the peptides. ∆Hvdw-p2 of M2Y is also lower than 
other kinds of peptide. The indole group of M2W and the aromatic rings of M2Y peptide 
have a large contribution to hydrophobic interaction in B-binding pocket. Accordingly, 
the energetic gain in van der Waals term seems some degree of correlation with the total 
binding affinity. The p2 anchor residue should have a large hydrophobicity to enhance 
the binding affinity to HLA-β2m. The indole group of Trp is important to enhance the 
binding with the B-pocket of HLA. The hydroxyl group of Tyr is also important for 
binding with the formation of hydrogen bond. The importance of hydrogen bond by Tyr 
was also suggested in the recent report that HIV changes its residues from Tyr to Phe to 
escape from the immunotherapy using a peptide vaccine.148  
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Table 3.3: Components of the binding free energy between p2 residue and HLA 
peptide 
∆Hele_p2 
(kcal/mol) 
∆Hvwd_p2 
(kcal/mol) 
∆Hint_p2 
(kcal/mol) 
∆Hsol_p2 
(kcal/mol) 
∆Hp2* 
(kcal/mol) 
NP -20.7 -10.1 8.1 5.3 -17.4 
M2Y -17.6 -13.4 7.9 4.6 -18.5 
M2W -17.8 -15.4 8.6 7.0 -17.6 
M2V -27.4 -6.8 8.2 3.3 -22.7 
M2I -23.8 -8.7 8.1 4.9 -19.9 
M2L -19.5 -7.9 7.8 2.8 -16.8 
M2A -20.3 -4.9 8.1 3.5 -13.6 
M2F -15.9 -9.5 8.5 1.0 -15.9 
M2G -12.6 -3.6 9.2 2.0 -5.0 
M2S -39.5 -3.0 7.7 14.7 -20.1 
M2T -19.6 -6.9 7.7 6.7 -12.1 
M2P -9.9 -7.7 9.3 1.9 -6.4 
M2C -20.7 -6.0 7.8 4.5 -14.4 
M2N -23.8 -8.2 8.6 9.6 -13.8 
M2Q -30.7 -8.8 8.2 14.1 -17.2 
M2H -21.3 -10.3 8.0 7.5 -16.1 
M2K -115.4 -6.9 8.1 104.0 -10.2 
M2R -103.7 -10.5 8.5 93.8 -11.9 
M2D 25.5 -6.8 7.6 -36.6 -10.3 
M2E 31.7 -7.3 8.7 -44.0 -10.9 
Abbreviation: NP, natural peptide; ∆Hele_p2, electrostatic energy; ∆Hvdw_p2, van der Walls interaction; 
∆Hint_p2, internal energy from bond, angle and dihedral; ∆Hsol_p2, solvation energy; ∆Hp2*, total binding 
free energy between p2 residue and HLA-β2m.  
  
 
74 
III.3.5 Energy calculation with another type of HLA 
As an example for predicting binding affinity between epitope and HLA, similar 
calculation were carried out for HLA-A*0201 and 4 kinds of peptide.147 HLA-A*0201, as 
well as HLA-A*2402, is one of the most popular HLA types in Japan. Table 3.4 shows 
the calculated binding free energy, in which computational prediction was compatible 
with the experimentally measured affinity of the peptide binding to HLA-A*0201. These 
results suggest that our present approach is one of the effective techniques to select the 
favorable peptides as HLA epitope. We have also examined the role of p2 residue of 
peptide in binding to HLA-β2m in this example. In the calculation, a large van der Waals 
interaction between the side chain of p2 residue and hydrophobic residues inside B-
pocket of HLA was observed.  
The application of MD simulation for selecting a peptide strongly bound to HLA 
was challenged in many research groups.149-152 Although there seems to be a room for 
improvement in practical use,149 the recent high-performance computers offer us a hope 
of accurate prediction of antigenic peptides.151 Some theoretical studies suggested the 
importance of the flexibility for peptide recognition.153,154 MD simulation is useful to 
obtain an insight into the dynamic behavior of molecules. For example, an increase in the 
peptide flexibility was observed in the binding groove.154 The conformational change of 
HLA molecule due to the peptide binding has been analyzed.155-157 Such a conformational 
change was shown to be closely related to the recognition of the peptide-HLA complex 
by CTLs,156 and the conformational difference between the peptide-bound and -unbound 
HLAs was clearly indicated by the removal of the bound peptide from a complex 
model.157 Nojima, et al. investigated the structural changes of the peptide-binding groove 
due to the removal of the peptide using the normal mode analysis.158,159 They suggested 
that two membrane-proximal domains had significant influence on the activity and 
stability of HLA.160,161 
The computational study is also advantageous to analyze the effect of amino acid 
substitution of epitope peptides.162-165 The reason for the change in peptide recognition 
among different types of HLA molecules has been clearly explained.166-168 In the 
computational studies, the accurate prediction of the complex structure of HLA and 
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peptide is essentially important and some trials were attempted for the construction of 
appropriate complex structures.169,170 Further, reliable estimation of the binding energy is 
indispensable for selecting a promising peptide, and MM-GB/SA and MM-Poisson-
Boltzmann (PB)/SA methods are the most standard approaches for estimating the binding 
energy.171,172  
All the above previous studies suggest the usefulness of molecular simulation for 
predicting the affinity and specificity of antigenic peptide binding to HLA. Because of 
the importance of peptide flexibility, the evaluation of entropic terms is indispensable for 
estimating peptide binding affinity. The prediction of the difference in binding affinity 
due to the amino acid substitution is possible through the theoretical calculations with 
high-performance computers of today. Accordingly, our present work will be one of the 
examples demonstrating an effectiveness of computational analysis, performed by taking 
full advantage of MD simulation.  
 
Table 3.4: Calculated binding free energy for several peptides binding to HLA-A*0201 
PDB ID Peptide sequence Kd (nM) ∆Gcalc(kcal/mol) 
1HHG TLTSVNTSV 294.0 6.0 
1HHJ ILKEPVHGV 242.0 9.7 
1HHK LLFGYPVYV 11.0 -1.8 
1HHI GILGFVFTL 6.0 -30.1 
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III.4 Conclusion 
We investigated the binding affinity between HLA-A*2402 and epitope peptide 
derived from Wilms’ tumor (WT1) protein, performing molecular dynamics simulations, 
followed by MM-GB/SA method and normal mode analysis. The binding affinity was 
also contrasted between the 9-mer natural WT1 peptide and the modified peptide in 
which 19 kinds of amino acids were substituted for Met located at the second residue of 
the N-terminal side. WT1 protein is highly expressed in solid tumor or blood in leukemia 
patient, and a vaccine targeting WT1 is expected to be one of the promising approaches 
in immunotherapy.119 In this work, we demonstrated that computational prediction of the 
peptide binding affinity to HLA is possible. The contribution of p2 residue of the epitope 
peptide to the binding free energy was due to the formation of hydrogen bond at the 
bottom of B-pocket of HLA and van der Waals interaction inside B-pocket. For the stable 
binding of epitope peptide to HLA-A*2402, p2 residue should have the following 
property. First, p2 residue should bear alkyl chain or aromatic ring to make van der 
Waals interaction strong enough inside B-pocket. Second, the residue containing polar 
atom is advantageous to make a hydrogen bond at the bottom of B-pocket. Third, the 
residue should have a large volume comparative to Tyr or Phe. These findings will be 
helpful to design the peptide vaccine inducing high immunological response or the 
peptide-mimic chemical for medical drugs.  
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Chapter IV 
 
Summary 
 The increase in number of the studies using molecular dynamics simulations on 
the properties of biological macromolecules is a consequence of the availability of 
software program and the development of the computer technology. The utility of 
computer simulation studies does not lie in the (still remote) possibility of replacing 
experimental measurement, but rather in its ability to complement experiments. 
Quantities that are inaccessible in experiment can be occasionally monitored in computer 
simulations. Computer  simulation  has  become  a  standard  tool  in  the  determination 
of spatial molecular structure on the  basis of X-ray diffraction or NMR data. Simulation 
is also helpful to predict the energy for inter molecular interaction.  
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